Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri, Fabiana Esposito, Lucia Cardillo, Kristian Taka, Lucrezia De Marchi, Marco Zomparelli, Kleda Zaganjori, Flavia Mallegni, Elisa Meddi, Federico Moretti, Ilaria Cerroni, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe
{"title":"开始治疗时间对急性髓系白血病患者强化化疗反应质量的影响。","authors":"Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri, Fabiana Esposito, Lucia Cardillo, Kristian Taka, Lucrezia De Marchi, Marco Zomparelli, Kleda Zaganjori, Flavia Mallegni, Elisa Meddi, Federico Moretti, Ilaria Cerroni, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe","doi":"10.3390/cancers17122028","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.</p><p><strong>Methods: </strong>This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.</p><p><strong>Results: </strong>Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (<i>p</i> = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (<i>p</i> = 0.004 and <i>p</i> = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.</p><p><strong>Conclusions: </strong>This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191022/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.\",\"authors\":\"Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri, Fabiana Esposito, Lucia Cardillo, Kristian Taka, Lucrezia De Marchi, Marco Zomparelli, Kleda Zaganjori, Flavia Mallegni, Elisa Meddi, Federico Moretti, Ilaria Cerroni, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe\",\"doi\":\"10.3390/cancers17122028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.</p><p><strong>Methods: </strong>This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.</p><p><strong>Results: </strong>Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (<i>p</i> = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (<i>p</i> = 0.004 and <i>p</i> = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.</p><p><strong>Conclusions: </strong>This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.</p>\",\"PeriodicalId\":9681,\"journal\":{\"name\":\"Cancers\",\"volume\":\"17 12\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191022/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/cancers17122028\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17122028","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.
Background: Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.
Methods: This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.
Results: Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (p = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (p = 0.004 and p = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.
Conclusions: This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.
期刊介绍：
Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
